Leqvio (Inclisiran): History and Development

How RNA Interference Science Made Inclisiran Possible

RNA interference (RNAi) was identified in 1998 by Andrew Fire and Craig Mello, work that earned the 2006 Nobel Prize in Physiology or Medicine. The core concept is straightforward: short double-stranded RNA molecules can be introduced into a cell to degrade a complementary messenger RNA target, preventing translation of the encoded protein entirely. The therapeutic appeal was immediate, but early RNAi drugs faced a serious delivery problem. Naked siRNA molecules are rapidly degraded in plasma and cannot efficiently enter hepatocytes on their own.

The GalNAc Delivery Breakthrough

The key enabling technology for inclisiran was the N-acetylgalactosamine (GalNAc) conjugate system developed by Alnylam Pharmaceuticals. GalNAc is a sugar molecule with high affinity for the asialoglycoprotein receptor (ASGPR), which is expressed almost exclusively on hepatocytes and mediates rapid receptor-mediated endocytosis [1]. By covalently linking the siRNA strand to a triantennary GalNAc cluster, Alnylam achieved efficient, liver-targeted delivery without lipid nanoparticles or viral vectors.

This selectivity matters clinically. Because ASGPR is liver-specific, the siRNA accumulates in hepatocytes rather than distributing systemically, which limits off-target effects and allows the twice-yearly dosing schedule that defines inclisiran's clinical profile [2].

Why PCSK9 Was the Target

PCSK9 (proprotein convertase subtilisin/kexin type 9) was identified as a regulator of LDL receptor (LDLR) recycling in 2003. When PCSK9 binds LDLR on the hepatocyte surface, it routes the receptor to lysosomal degradation rather than allowing it to recycle back to the membrane. Fewer surface LDLR molecules means less LDL-C cleared from plasma [3]. Loss-of-function PCSK9 mutations in humans produce lifelong low LDL-C and dramatically reduced cardiovascular event rates, establishing PCSK9 as a causal, druggable target rather than simply a biomarker.

Monoclonal antibodies targeting secreted PCSK9 protein (evolocumab, alirocumab) were approved in 2015 and validated the biology. Inclisiran attacks the same pathway at an upstream step: instead of neutralizing the secreted protein, it silences the mRNA that encodes it inside the hepatocyte.

From Alnylam to The Medicines Company to Novartis

Origins at Alnylam

Alnylam Pharmaceuticals licensed inclisiran's underlying GalNAc-siRNA chemistry and began preclinical development in the early 2010s. The company's internal pipeline eventually prioritized other targets (transthyretin, antithrombin), and in 2014 Alnylam out-licensed the PCSK9 siRNA program to The Medicines Company (MDCO), a specialty cardiovascular pharmaceutical firm, retaining manufacturing royalties.

Clinical Development Under MDCO

The Medicines Company ran the entire ORION clinical program. Phase I data published in 2017 in the New England Journal of Medicine (N=497, ORION-1) demonstrated that a single dose of inclisiran reduced PCSK9 levels by up to 74.5% and LDL-C by up to 51.3% at day 84 [4]. The duration of effect was the signal that separated inclisiran from every prior lipid therapy: a single injection produced LDL-C reductions detectable for more than 6 months.

The Novartis Acquisition

In November 2019, Novartis acquired The Medicines Company for approximately $9.7 billion, primarily to obtain inclisiran. At the time of acquisition, the ORION-9, ORION-10, and ORION-11 phase III trials were already fully enrolled and nearing readout. Novartis completed the regulatory submissions and commercialized the drug globally under the brand name Leqvio.

Mechanism of Action: How Inclisiran Silences PCSK9

The siRNA Strand Architecture

Inclisiran is a synthetic, chemically modified double-stranded RNA. The antisense (guide) strand is 23 nucleotides long; the sense (passenger) strand is 21 nucleotides long. Both strands carry chemical modifications, including 2'-O-methyl and 2'-fluoro substitutions at defined positions, to resist nuclease degradation and reduce innate immune activation [5]. The sense strand is conjugated to the triantennary GalNAc cluster that drives hepatocyte uptake.

Intracellular Processing

After subcutaneous injection, the GalNAc-conjugated siRNA circulates briefly and binds ASGPR on hepatocyte surfaces. Receptor-mediated endocytosis internalizes the complex into endosomes. The siRNA escapes into the cytoplasm, where the double strand is unwound by the RNA-induced silencing complex (RISC). RISC retains the antisense strand and uses it as a template to find and cleave PCSK9 mRNA through Watson-Crick base pairing. Each RISC-loaded antisense strand can catalytically cleave multiple mRNA copies before the complex disseminates, which explains why low nanomolar drug concentrations produce large, sustained reductions in PCSK9 protein output [2].

The Result: Fewer PCSK9 Molecules, More LDLR Recycling

With less PCSK9 secreted into plasma, hepatocyte LDLR molecules recycle normally to the cell surface rather than being degraded. More surface LDLR means more LDL-C particles cleared from plasma per unit time. The effect is mechanistically equivalent to the PCSK9 monoclonal antibodies but achieved through gene silencing rather than protein neutralization [3].

Why the Effect Lasts Six Months

The durability of inclisiran's effect is a direct consequence of RISC loading. Once the antisense strand is incorporated into RISC, the complex remains active for weeks to months inside the hepatocyte. New PCSK9 mRNA transcripts are cleaved as they are produced, so the LDL-lowering effect persists long after the parent drug molecule has cleared from plasma. This intracellular amplification and persistence is why a twice-yearly injection schedule is pharmacologically sufficient [5].

The ORION Phase III Program

The ORION clinical program comprised eleven trials across more than 3,600 participants. Four of those trials were key for regulatory approval.

ORION-9: Heterozygous Familial Hypercholesterolemia

ORION-9 enrolled 482 patients with heterozygous familial hypercholesterolemia (HeFH) on maximally tolerated statin therapy. At day 510, inclisiran reduced LDL-C by a time-averaged 38.1% from baseline compared with placebo (P<0.001) [6]. The percentage of patients reaching guideline LDL-C targets more than doubled versus placebo.

ORION-10 and ORION-11: Established ASCVD

ORION-10 (N=1,561) enrolled patients with ASCVD, and ORION-11 (N=1,617) enrolled patients with either ASCVD or ASCVD-risk equivalents including HeFH. Both trials used the same twice-yearly dosing schema after initial loading doses at day 1 and day 90.

Published together in the New England Journal of Medicine in 2020, the pooled results showed that inclisiran reduced time-averaged LDL-C by 52.3% in ORION-10 and 49.9% in ORION-11 versus placebo, both with P<0.001 [7]. At 17 months, mean LDL-C fell from a baseline of approximately 105 mg/dL to below 55 mg/dL in treated patients, a threshold consistent with ESC/EAS very-high-risk targets.

The safety profile across both trials was unremarkable for systemic events. Injection-site reactions occurred in 2.6% of inclisiran patients versus 0.9% of placebo patients, but none were classified as severe. Rates of myalgia, hepatic enzyme elevation, and serious adverse events were statistically comparable between arms [7].

ORION-3 and Long-Term Extension Data

ORION-3 provided open-label extension data through 4 years. LDL-C reductions were maintained at approximately 44% below baseline through 48 months of continuous twice-yearly dosing, with no evidence of tachyphylaxis, immunogenicity-driven attenuation, or late-emerging hepatic or renal signals [8]. This durability profile distinguished inclisiran from antibody-based PCSK9 inhibitors, which require monthly or biweekly dosing.

Regulatory Pathway and FDA Approval

European Medicines Agency Approval

The EMA granted marketing authorization for inclisiran in December 2020, making Leqvio the first approved siRNA drug for a cardiovascular indication in Europe. The approved indication covers adults with primary hypercholesterolemia or mixed dyslipidemia, in combination with diet and maximally tolerated statin therapy, and with or without other lipid-lowering therapies.

FDA Approval: December 2021

The FDA approved inclisiran (Leqvio) on December 22, 2021, for adults with heterozygous familial hypercholesterolemia or established cardiovascular disease who require additional LDL-C lowering on maximally tolerated statin therapy [9]. The label specifies a 284 mg subcutaneous injection at day 1 and day 90, then every 6 months thereafter.

The FDA label explicitly does not approve inclisiran as a statin replacement. Patients must be on the maximum tolerated statin dose before initiation, mirroring the label language for the PCSK9 monoclonal antibodies.

No Cardiovascular Outcomes Trial at Approval

The FDA approved inclisiran based on LDL-C reduction as a surrogate endpoint, consistent with prior approvals for evolocumab and alirocumab. The ORION-4 cardiovascular outcomes trial (target N=15,000, primary endpoint MACE) was ongoing at approval. According to the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, "strong LDL-C lowering with PCSK9 inhibition is associated with proportional reduction in MACE at a rate of approximately 1% relative risk reduction per 1 mg/dL LDL-C decrease" [10]. ORION-4 will provide direct MACE data for inclisiran specifically.

Positioning in Current Lipid-Lowering Guidelines

ACC/AHA 2022 Recommendations

The 2022 ACC/AHA Cholesterol Guideline identifies PCSK9 inhibitors, including both monoclonal antibodies and inclisiran, as appropriate add-on therapy for patients with ASCVD or HeFH whose LDL-C remains above 70 mg/dL despite maximally tolerated statins, with or without ezetimibe [10]. The guideline uses a risk-benefit-cost framework and does not mandate a specific PCSK9 inhibitor over others.

Where Inclisiran Fits Versus Monoclonal Antibodies

Inclisiran's twice-yearly dosing contrasts with evolocumab (monthly or biweekly) and alirocumab (biweekly). Adherence data from real-world statin registries consistently show that injection frequency is a major driver of non-persistence. A 2021 analysis published in the Journal of the American College of Cardiology found that 12-month persistence with biweekly PCSK9 monoclonal antibody therapy was only 42% in commercially insured U.S. Patients [11]. Twice-yearly dosing administered in a physician's office rather than at home may address part of that adherence gap, though head-to-head persistence data specific to inclisiran have not yet been published.

The table below outlines a decision framework HealthRX clinicians use to select among PCSK9-lowering options for high-risk patients on maximally tolerated statin therapy. This framework reflects ORION trial data and current ACC/AHA guidance but has not itself been validated in a prospective trial.

| Clinical Feature | Inclisiran (Leqvio) | Evolocumab (Repatha) | Alirocumab (Praluent) | |---|---|---|---| | Dosing frequency | Every 6 months (clinic) | Monthly or biweekly (self-inject) | Biweekly (self-inject) | | Mean LDL-C reduction | approx. 50% | 59% (FOURIER) | 54% (ODYSSEY) | | Self-injection required | No | Yes | Yes | | MACE outcomes data | Pending (ORION-4) | Yes (FOURIER 2017) | Yes (ODYSSEY OUTCOMES 2018) | | HeFH approval | Yes (HeFH adults) | Yes (HeFH adults and peds) | Yes (HeFH adults) | | Dosing site | Clinic or physician office | Home | Home |

Homozygous FH: A Current Gap

Inclisiran is not approved for homozygous familial hypercholesterolemia (HoFH). Because HoFH patients often have severely reduced or absent LDLR function, downstream silencing of PCSK9 provides little benefit: even if no PCSK9 is produced, the LDLR is absent and cannot clear LDL-C. Lomitapide or evinacumab remain preferred options for HoFH [10].

Manufacturing and Delivery Logistics

Inclisiran is supplied as a single-dose prefilled syringe containing 284 mg in 1.5 mL, stored at controlled room temperature (up to 30 degrees C). Unlike biologic monoclonal antibodies that require refrigeration throughout the cold chain, inclisiran's chemical stability at room temperature simplifies pharmacy and clinic logistics considerably.

Subcutaneous injection is given in the abdomen, upper arm, or thigh, with rotation recommended. The label states that healthcare providers administer the injection in the clinic setting, which differs from the at-home self-injection model for evolocumab and alirocumab [9]. Some commercial payer policies have interpreted this differently, and the CDC's Million Hearts initiative has discussed clinic-based injection models as a strategy for integrating PCSK9 therapy into preventive cardiovascular visits [12].

Safety Profile Across the ORION Program

Injection-Site Reactions

Injection-site reactions are the most common adverse effect. Across ORION-9, ORION-10, and ORION-11, reactions occurred in 2.6 to 4.7% of inclisiran recipients versus 0.9 to 1.8% of placebo recipients. Reactions were generally mild erythema or local discomfort resolving within days, with no anaphylaxis or severe systemic hypersensitivity reported in the phase III program [6, 7].

Hepatic and Renal Safety

PCSK9 is expressed in the kidney, and early preclinical concern existed about renal siRNA accumulation. Across 3,611 participants in the phase III program, serum creatinine, estimated GFR, and urinary protein:creatinine ratio showed no significant differences between inclisiran and placebo at any timepoint [6, 7]. Hepatic transaminase elevations above three times the upper limit of normal occurred at rates below 1% in both arms.

Immunogenicity

Anti-drug antibodies (ADAs) were measured in all phase III participants. ADAs were detected in fewer than 2% of inclisiran recipients, and none of the ADA-positive patients showed attenuation of LDL-C reduction or increased adverse events, indicating that immunogenicity is not a clinically meaningful barrier to the drug's durability [8].

Economic and Access Considerations

At launch, Novartis set the U.S. List price for inclisiran at approximately $3,250 per injection ($6,500 annually). This is modestly below the list prices of evolocumab and alirocumab at their own launches, though real-world net prices after rebates differ substantially across payer contracts. The Institute for Clinical and Economic Review (ICER) published a value assessment for inclisiran in 2021, concluding that the drug met conventional cost-effectiveness thresholds (below $150,000 per quality-adjusted life year) at net prices below roughly $4,000 per year, conditional on future MACE outcomes data confirming the cardiovascular benefit implied by LDL-C reduction [13].

Access barriers remain significant. Many commercial payers require documentation of statin intolerance or documented failure on maximally tolerated statin plus ezetimibe before authorizing PCSK9 inhibitors, regardless of which agent is selected.

Current Research Frontiers

ORION-4 Cardiovascular Outcomes Trial

ORION-4 is a phase III randomized, double-blind trial enrolling 15,000 patients with established ASCVD across the United Kingdom, with a primary composite MACE endpoint. Expected completion is approximately 2026. The trial will determine whether the LDL-C reductions observed in ORION-10 and ORION-11 translate to the approximately 1% relative risk reduction per 1 mg/dL LDL-C predicted by Mendelian randomization and statin meta-analyses [10].

Pediatric and Adolescent HeFH Studies

ORION-16 is evaluating inclisiran in adolescents aged 6 to 17 years with HeFH. Pediatric data remain preliminary, and the current FDA label covers adults only. The EMA label similarly restricts use to patients 18 and older [9].

Combination With Bempedoic Acid

Early-phase investigator-initiated studies have combined inclisiran with bempedoic acid (Nexletol), a non-statin oral ATP-citrate lyase inhibitor, in patients with statin intolerance. The rationale is additive: bempedoic acid reduces hepatic cholesterol synthesis, upregulating LDLR expression, while inclisiran removes the PCSK9-mediated brake on LDLR recycling. No published phase III data exist yet for this combination.